Intravenous Immunoglobulin Market Report 2025

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $14.66 billion in 2024 to $15.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders, management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $22.01 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches. Major trends in the forecast period include primary immunodeficiency disorders (PIDD) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

The growing geriatric population is anticipated to propel the intravenous immunoglobulin market in the coming years. The geriatric population is defined as individuals aged 65 and older. As people age, their immune systems often become less effective, leading to a deficiency in antibodies. Consequently, there is a heightened need for immunoglobulins to provide these necessary antibodies. This increasing demand for intravenous immunoglobulins contributes to the market's growth. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, reported that the population of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, the proportion of this age group within the overall population is expected to grow from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is set to drive the growth of the intravenous immunoglobulin market.

The rising prevalence of rheumatoid arthritis (RA) is expected to drive the growth of the intravenous immunoglobulin (IVIG) market in the coming years. RA is a chronic autoimmune condition that leads to inflammation, pain, swelling, and stiffness in the joints. If untreated, it can result in significant joint damage and disability. IVIG, a blood product containing antibodies from healthy donors, can help mitigate the inflammatory processes that contribute to joint damage in RA patients. For instance, in June 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that approximately 456,000 Australians (1.9%) are estimated to have rheumatoid arthritis. In 2022, RA was responsible for 2% of the total disease burden and 16% of the overall burden of musculoskeletal diseases. Furthermore, in July 2022, the National Rheumatoid Arthritis Society (NRAS), a UK-based nonprofit organization, estimated that over 450,000 individuals in the UK are living with rheumatoid arthritis, with the most common onset age being between 40 and 60, or slightly older for men. Thus, the increasing prevalence of rheumatoid arthritis is driving growth in the intravenous immunoglobulin (IVIG) market.

Product innovation is a significant trend gaining traction in the intravenous immunoglobulin (IVIG) market. Key players in the industry are concentrating on developing new products, such as liquid immune globulin formulations, to treat immunodeficiency diseases and maintain their competitive edge. For example, in December 2023, GC Pharma, a pharmaceutical company based in South Korea, launched Alyglo, a sterile, ready-to-use liquid formulation that has received approval from the U.S. Food and Drug Administration (FDA). This product contains 10% immunoglobulin G (IgG), providing 100 mg/mL of protein, of which at least 96% is human IgG derived from pooled human plasma. Alyglo is specifically indicated for treating primary humoral immunodeficiency (PI) in adults aged 17 years and older, addressing conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Major companies in the intravenous immunoglobulin (IVIG) market are concentrating on launching innovative products, such as plasma-derived medicines, and securing approvals from federal agencies like the U.S. Food and Drug Administration (FDA) to enhance their competitive position. The introduction of an FDA-approved innovative IVIG solution represents the official endorsement of a new intravenous immunoglobulin therapy by the FDA for treating specific medical conditions. For instance, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products, announced that it received its first FDA approval for Yimmugo, designed to treat primary immunodeficiencies (PIDs). As an intravenous immunoglobulin, Yimmugo contains pooled human plasma-derived immunoglobulin G (IgG), which is essential for providing immune support to patients with PIDs. This approval aligns with the growing demand for plasma-derived therapies, emphasizing the need for effective treatments for patients with weakened immune systems. Yimmugo expands Grifols' existing portfolio of intravenous and subcutaneous immunoglobulins, offering more options for patients dependent on these vital medications.

In February 2024, Ridgemont Equity Partners, a U.S.-based equity investment firm, acquired American Outcomes Management for an undisclosed amount. This acquisition supports Ridgemont's strategic focus on the expanding specialty infusion market, which is fueled by an aging population with chronic conditions and an increasing demand for at-home treatment options. American Outcomes Management is a U.S.-based provider of intravenous immunoglobulin (IVIG) infusion therapy.

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intravenous immunoglobulin therapy serves as a treatment for individuals with immunodeficiencies, administered through intravenous infusion. The infusion liquid derives from purified immunoglobulins sourced from healthy donors, rigorously cleansed to eliminate any potential blood-borne infections or impurities.

Key categories of intravenous immunoglobulins encompass IgG, IgM, IgA, IgE, and IgD. IgG, the prevalent immunoglobulin in bodily fluids, plays a pivotal role in safeguarding against bacterial and viral infections. Its application involves reinforcing the body's innate defense mechanisms. These products find distribution channels across hospital and retail pharmacies, serving various medical needs like hypogammaglobulinemia, CIDP, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, among others. The end-users span hospitals, clinics, and home care setups.

The intravenous immunoglobulin market research report is one of a series of new reports that provides intravenous immunoglobulin market statistics, including intravenous immunoglobulin industry global market size, regional shares, competitors with an intravenous immunoglobulin market share, detailed intravenous immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. This intravenous immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.